HOME >> BIOLOGY >> NEWS
Protein found that slows hepatitis C growth in liver cells

GALVESTON, Texas Biomedical researchers have identified a cellular protein that interferes with hepatitis C virus replication, a finding that ultimately may help scientists develop new drugs to fight the virus.

The anti-hepatitis C activity of the protein, called p21-activated kinase 1 (PAK1), was discovered by scientists at the University of Texas Medical Branch at Galveston (UTMB), who describe their findings in an article in the current issue of the Journal of Biological Chemistry. In addition to presenting the researchers discovery that PAK1 controls the rate at which hepatitis C virus replicates, the paper describes the biochemical pathways that lead to PAK1 activation and the specific mechanisms by which PAK1 interferes with the ability of hepatitis C to hijack liver cells and make more copies of itself.

Our findings reveal a novel cellular control pathway that regulates the growth of hepatitis C virus within the cell, said Dr. Stanley M. Lemon, director of the National Institutes of Health-funded Hepatitis C Research Center at UTMB and of the academic medical centers Institute for Human Infections and Immunity. Lemon, senior author of the Journal of Biological Chemistry paper, added, Understanding this better is likely to suggest new approaches to therapy for this difficult to treat disease."

Hepatitis C chronically infects approximately 170 million people worldwide. The most effective treatment for the virus, interferon-based therapy, eradicates the virus less than 50 percent of the time and causes debilitating side effects. Those for whom that treatment fails are at high risk for fatal cirrhosis or liver cancer. In the United States, about half of all liver cancer cases occur in people infected by hepatitis C virus.

The UTMB scientists reported their findings in the April 20 issue of the Journal of Biological Chemistry. Their article is entitled P21-activated Kinase 1 Is Activated through the Mammalian Target of R
'"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
26-Apr-2007


Page: 1 2

Related biology news :

1. Protein chatter linked to cancer activation
2. Coming soon -- Protein synthesis without amino acids?
3. Protein pulling -- Learning how proteins fold by pulling them apart
4. Protein interactions targets for Huntington disease therapy
5. Protein enables discovery of quantum effect in photosynthesis
6. Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex
7. Protein averts cell suicide but might contribute to cancer
8. Protein structures for the entire yeast proteome
9. Protein overexpression at heart of heart failure
10. Protein sciences
11. Protein identified that regulates effectiveness of Taxol chemotherapy in breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2019)... ... December 03, 2019 , ... ... technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer ... Ethicann Pharmaceuticals Inc. (“Ethicann”), a Calgary-based pharmaceutical company using botanically sourced cannabinoid ...
(Date:11/27/2019)... (PRWEB) , ... November 25, 2019 , ... Though the ... for the more than 55 million travelers expected to hit the roads and the ... application worth it’s weight in truffle oil will offer a simple design, mouth-watering pictures ...
(Date:11/22/2019)... N.Y. (PRWEB) , ... November 21, 2019 , ... ... developed at Roswell Park Comprehensive Cancer Center have announced a major step forward ... Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park ...
Breaking Biology News(10 mins):
(Date:12/18/2019)... , ... December 17, 2019 , ... ... its 31st FDA clearance for reprocessing Electrophysiology (EP) devices since the company’s inception ... Stryker Sustainability Solutions and SterilMed (a Johnson & Johnson company) have received 2 ...
(Date:12/18/2019)... ... 2019 , ... Tune in to CNBC on Saturday, December 28th at 11:00aET ... for more information on this program. , With a look at Avatar Partners ... system to increase the efficiency, safety and effectiveness of equipment, systems, and processes for ...
(Date:12/6/2019)... ... December 06, 2019 , ... ... has received FDA 510(k) clearance for its latest CAPERE® Thrombectomy System for ... suggests the CAPERE® offers great benefits for first-in-line treatment for nonsurgical removal ...
(Date:12/4/2019)... ... December 03, 2019 , ... Absolute Antibody ... a partnership with the Recombinant Antibody Network (RAN), a consortium of three expert ... (UCSF) with a common goal to generate recombinant antibodies at a proteome-wide scale. ...
Breaking Biology Technology:
Cached News: